The estimated Net Worth of Julie M Cherrington is at least $2.83 Million dollars as of 19 January 2022. Julie Cherrington owns over 1,475 units of Mirati Therapeutics Inc stock worth over $149,450 and over the last 5 years he sold MRTX stock worth over $686,928. In addition, he makes $1,990,700 as Independent Director at Mirati Therapeutics Inc.
Julie has made over 3 trades of the Mirati Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,546 units of MRTX stock worth $113,704 on 18 January 2023.
The largest trade he's ever made was selling 2,546 units of Mirati Therapeutics Inc stock on 18 January 2023 worth over $113,704. On average, Julie trades about 502 units every 57 days since 2019. As of 19 January 2022 he still owns at least 2,546 units of Mirati Therapeutics Inc stock.
You can see the complete history of Julie Cherrington stock trades at the bottom of the page.
Dr. Julie M. Cherrington Ph.D. serves as Independent Director of the Company. She has served as a member of our Board of Directors since June 2019. Dr. Cherrington is currently the President and Chief Executive Officer of Arch Oncology, Inc. a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs, a position she has held since October 2017. Previously, she has served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Inc. from September 2015 to April 2017, Zenith Epigenetics from 2014 to 2015, and Pathway Therapeutics, a company advancing targeted kinase inhibitors for the treatment of cancer, from 2009 to 2013. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. She is also currently on the board of directors of Que Oncology. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.
As the Independent Director of Mirati Therapeutics Inc, the total compensation of Julie Cherrington at Mirati Therapeutics Inc is $1,990,700. There are 3 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of $8,484,390.
Julie Cherrington is 62, he's been the Independent Director of Mirati Therapeutics Inc since 2019. There are 3 older and 14 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Julie's mailing address filed with the SEC is C/O MIRATI THERAPEUTICS, INC., 3545 CRAY COURT, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza..., and Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: